Association between Hyperreflective Foci on Spectral-Domain Optical Coherence Tomography and Early Recurrence of Diabetic Macular Edema after Intravitreal Dexamethasone Implantation

被引:14
作者
Kim, Kyung Tae [1 ]
Kim, Dong Yoon [2 ]
Chae, Ju Byung [2 ]
机构
[1] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Ophthalmol, Ulsan, South Korea
[2] Chungbuk Natl Univ, Coll Med, Chungbuk Natl Univ Hosp, Dept Ophthalmol, Cheongju, South Korea
关键词
CONTROLLED-TRIAL; VISUAL OUTCOMES; OUTER RETINA; REAL-LIFE; FOLLOW-UP; RETINOPATHY; THERAPY; BEVACIZUMAB; PREVALENCE; ACTIVATION;
D O I
10.1155/2019/3459164
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose. To investigate the associations between hyperreflective foci (HRF) on spectral-domain optical coherence tomography (SD-OCT) and early recurrence of macular edema after intravitreal dexamethasone (DEX) implantation in eyes with refractory diabetic macular edema (DME) to bevacizumab. Methods. Medical records of patients with refractory DME to bevacizumab, who underwent intravitreal DEX implantation and 12-month follow-up, were reviewed. Eyes in which central subfield thickness (CST) increased over 50 mu m at 3 months compared with the first month after intravitreal DEX implantation were categorized into the early recurrence group, and the others were categorized into the late recurrence group. Best-corrected visual acuity (BCVA), CST, and number of HRF on SD-OCT were analyzed. Results. Twenty-nine eyes of 26 patients (16 eyes in the early recurrence group and 13 eyes in the late recurrence group) were included in this study. The numbers of HRF in entire retina, inner retina, and outer retina at baseline in the early recurrence group (11.38 +/- 3.07 in entire retina, 5.44 +/- 1.50 in inner retina, 5.94 +/- 2.74 in outer retina) were significantly greater than those in the late recurrence group (7.54 +/- 3.60 in entire retina, p=0.006; 4.08 +/- 1.70 in inner retina, p=0.034; 3.46 +/- 2.30 in outer retina, p=0.013). Multivariate logistic regression analysis showed that a higher number of HRF increased the risk of early recurrence after intravitreal DEX implantation (odds ratio in entire retina: 1.518, p=0.012; odds ratio in inner retina: 2.058, p=0.027; odds ratio in outer retina: 1.610, p=0.029). Conclusions. Higher baseline numbers of HRF on SD-OCT may be a predictive indicator of early recurrence of macular edema after intravitreal DEX implantation for DME.
引用
收藏
页数:9
相关论文
共 38 条
[1]   Longitudinal Study of Sustained-Release Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema [J].
Aknin, Isabelle ;
Melki, Laurent .
OPHTHALMOLOGICA, 2016, 235 (04) :187-188
[2]   INTRAVITREAL DEXAMETHASONE IMPLANT FOR THE TREATMENT OF REFRACTORY MACULAR EDEMA IN RETINAL VASCULAR DISEASES Results of the KKESH International Collaborative Retina Study Group [J].
Alshahrani, Saeed T. ;
Dolz-Marco, Rosa ;
Gallego-Pinazo, Roberto ;
Diaz-Llopis, Manuel ;
Arevalo, J. Fernando .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (01) :131-136
[3]  
Bahrami B, 2017, ASIA-PAC J OPHTHALMO, V6, P535, DOI 10.22608/APO.2017350
[4]   Optical Coherence Tomographic Hyperreflective Foci A Morphologic Sign of Lipid Extravasation in Diabetic Macular Edema [J].
Bolz, Matthias ;
Schmidt-Erfurth, Ursula ;
Deak, Gabor ;
Mylonas, Georgios ;
Kriechbaum, Katharina ;
Scholda, Christoph .
OPHTHALMOLOGY, 2009, 116 (05) :914-920
[5]   Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema [J].
Boyer, David S. ;
Yoon, Young Hee ;
Belfort, Rubens, Jr. ;
Bandello, Francesco ;
Maturi, Raj K. ;
Augustin, Albert J. ;
Li, Xiao-Yan ;
Cui, Harry ;
Hashad, Yehia ;
Whitcup, Scott M. .
OPHTHALMOLOGY, 2014, 121 (10) :1904-1914
[6]   Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studies [J].
Bucolo, Claudio ;
Gozzo, Lucia ;
Longo, Laura ;
Mansueto, Silvana ;
Vitale, Daniela Cristina ;
Drago, Filippo .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2018, 138 (04) :219-232
[7]   Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant [J].
Chang-Lin, Joan-En ;
Attar, Mayssa ;
Acheampong, Andrew A. ;
Robinson, Michael R. ;
Whitcup, Scott M. ;
Kuppermann, Baruch D. ;
Welty, Devin .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2011, 52 (01) :80-86
[8]   HYPERREFLECTIVE FOCI AS AN INDEPENDENT VISUAL OUTCOME PREDICTOR IN MACULAR EDEMA DUE TO RETINAL VASCULAR DISEASES TREATED WITH INTRAVITREAL DEXAMETHASONE OR RANIBIZUMAB [J].
Chatziralli, Irini P. ;
Sergentanis, Theodoros N. ;
Sivaprasad, Sobha .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (12) :2319-2328
[9]   Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema [J].
Dutra Medeiros, Marco ;
Postorino, Maurizio ;
Navarro, Rafael ;
Garcia-Arumi, Jose ;
Mateo, Carlos ;
Corcostegui, Borja .
OPHTHALMOLOGICA, 2014, 231 (03) :141-146
[10]   Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema [J].
Elman, Michael J. ;
Bressler, Neil M. ;
Qin, Haijing ;
Beck, Roy W. ;
Ferris, Frederick L., III ;
Friedman, Scott M. ;
Glassman, Adam R. ;
Scott, Ingrid U. ;
Stockdale, Cynthia R. ;
Sun, Jennifer K. .
OPHTHALMOLOGY, 2011, 118 (04) :609-614